THE OUTCOME OF PERIPHERAL T-CELL LYMPHOMA PATIENTS FAILING FIRST-LINE THERAPY, FROM PROSPECTIVE COHORT OF T-CELL BRAZIL PROJECT
Objective: In Brazil, the National Institute of Cancer estimates for the years 2023-2025 about 12,040 new cases of NHL, about 1,444 of peripheral T-cell lymphomas (PTCLs). T-cell Brazil project is an ambispective study inserting new diagnosis from January 2015 to December 2022. Our goal was to explo...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137923001992 |
| _version_ | 1797663757279690752 |
|---|---|
| author | Carmino De Souza Eliana Miranda Jamila Tavares Renata LR Baptista Karin C Cecyn Juliana Pereira Marcelo Bellesso Samuel S Medina Davimar Borducchi Frederico L Nogueira Daniela FC Farias Thais Fischer Rony Schaffel Massimo Federico Carlos S Chiattone |
| author_facet | Carmino De Souza Eliana Miranda Jamila Tavares Renata LR Baptista Karin C Cecyn Juliana Pereira Marcelo Bellesso Samuel S Medina Davimar Borducchi Frederico L Nogueira Daniela FC Farias Thais Fischer Rony Schaffel Massimo Federico Carlos S Chiattone |
| author_sort | Carmino De Souza |
| collection | DOAJ |
| description | Objective: In Brazil, the National Institute of Cancer estimates for the years 2023-2025 about 12,040 new cases of NHL, about 1,444 of peripheral T-cell lymphomas (PTCLs). T-cell Brazil project is an ambispective study inserting new diagnosis from January 2015 to December 2022. Our goal was to explore a prospective cohort (PC), April 2017-December 2022, analyzing primary refractory and relapse (R/R) PTCLs pts to explore bad factors for overall survival (OS). Methodology: PC enrolled 461 pts who received 1ª treatment line. Descriptive analyses, Kaplan-Meier method, Log-Rank test to compare groups and Cox Regression to identify risk factor for OS using IBM-SPSS software v.24. Results: It was identified 171 (37%) pts, 71% refractory and 29% relapsed. Median mo. from treatment to R/R was 6 mo. (1-49). Overall, 42% received 2nd line treatment and these 11% had to bone marrow transplantation. After a median 17 months (0-51) of follow up, 64% pts had died, and 74% due to lymphoma, 17% infections, 9% toxicities.Refractory pts (HR=2.51, P<0.0001), IPI=2-4 (HR=3.19, P<0.0001) and >1 extranodal site (HR=1.76, P=0.01) were associated with a higher risk of death in a Cox Regression. Conclusion: This study confirms outcomes for patients treated according to standards treatment. No difference was found in OS with respect to histology. Results confirm that peripheral T-cell lymphomas patients had dismal outcome after relapse or progression, besides of higher IPI and more than one extranodal site at diagnosis. However, HCT as salvage can possibly prolong life as some studies already indicated. |
| first_indexed | 2024-03-11T19:19:22Z |
| format | Article |
| id | doaj.art-a98eb2a4703a4e818d1a356b219f95a3 |
| institution | Directory Open Access Journal |
| issn | 2531-1379 |
| language | English |
| last_indexed | 2024-03-11T19:19:22Z |
| publishDate | 2023-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj.art-a98eb2a4703a4e818d1a356b219f95a32023-10-08T04:35:44ZengElsevierHematology, Transfusion and Cell Therapy2531-13792023-10-0145S13S14THE OUTCOME OF PERIPHERAL T-CELL LYMPHOMA PATIENTS FAILING FIRST-LINE THERAPY, FROM PROSPECTIVE COHORT OF T-CELL BRAZIL PROJECTCarmino De Souza0Eliana Miranda1Jamila Tavares2Renata LR Baptista3Karin C Cecyn4Juliana Pereira5Marcelo Bellesso6Samuel S Medina7Davimar Borducchi8Frederico L Nogueira9Daniela FC Farias10Thais Fischer11Rony Schaffel12Massimo Federico13Carlos S Chiattone14Samaritano Hospital – Higienopolis & Santa Casa Medical School of Sao PauloSamaritano Hospital – Higienopolis & Santa Casa Medical School of Sao PauloUniversity of Campinas (UNICAMP), Hematology and Hemotherapy Center, SPOphir Loyola Hospital, Belem, PAState University of Rio de Janeiro – UERJ & Instituto D'Or de Pesquisa e Ensino (IDOR), Rio de JaneiroFederal University of Sao Paulo - UNIFESP, SPMedicine School of University of São Paulo – USP, SPSamaritano Hospital – Higienopolis & Santa Casa Medical School of Sao PauloHemoMed, Instituto de Ensino e Pesquisa – IEP, São Lucas, SPMedical School of ABC, Santo Andre, SPHospital Luxemburgo, Instituto Mario Penna, MGHospital Beneficencia Portuguesa, SPAC Camargo Hospital Cancer Center, SPFederal University of Rio de Janeiro – UFRJ, Clementino Fraga Hospital, RJUniversity of Modena and Reggio Emília, ItalyObjective: In Brazil, the National Institute of Cancer estimates for the years 2023-2025 about 12,040 new cases of NHL, about 1,444 of peripheral T-cell lymphomas (PTCLs). T-cell Brazil project is an ambispective study inserting new diagnosis from January 2015 to December 2022. Our goal was to explore a prospective cohort (PC), April 2017-December 2022, analyzing primary refractory and relapse (R/R) PTCLs pts to explore bad factors for overall survival (OS). Methodology: PC enrolled 461 pts who received 1ª treatment line. Descriptive analyses, Kaplan-Meier method, Log-Rank test to compare groups and Cox Regression to identify risk factor for OS using IBM-SPSS software v.24. Results: It was identified 171 (37%) pts, 71% refractory and 29% relapsed. Median mo. from treatment to R/R was 6 mo. (1-49). Overall, 42% received 2nd line treatment and these 11% had to bone marrow transplantation. After a median 17 months (0-51) of follow up, 64% pts had died, and 74% due to lymphoma, 17% infections, 9% toxicities.Refractory pts (HR=2.51, P<0.0001), IPI=2-4 (HR=3.19, P<0.0001) and >1 extranodal site (HR=1.76, P=0.01) were associated with a higher risk of death in a Cox Regression. Conclusion: This study confirms outcomes for patients treated according to standards treatment. No difference was found in OS with respect to histology. Results confirm that peripheral T-cell lymphomas patients had dismal outcome after relapse or progression, besides of higher IPI and more than one extranodal site at diagnosis. However, HCT as salvage can possibly prolong life as some studies already indicated.http://www.sciencedirect.com/science/article/pii/S2531137923001992 |
| spellingShingle | Carmino De Souza Eliana Miranda Jamila Tavares Renata LR Baptista Karin C Cecyn Juliana Pereira Marcelo Bellesso Samuel S Medina Davimar Borducchi Frederico L Nogueira Daniela FC Farias Thais Fischer Rony Schaffel Massimo Federico Carlos S Chiattone THE OUTCOME OF PERIPHERAL T-CELL LYMPHOMA PATIENTS FAILING FIRST-LINE THERAPY, FROM PROSPECTIVE COHORT OF T-CELL BRAZIL PROJECT Hematology, Transfusion and Cell Therapy |
| title | THE OUTCOME OF PERIPHERAL T-CELL LYMPHOMA PATIENTS FAILING FIRST-LINE THERAPY, FROM PROSPECTIVE COHORT OF T-CELL BRAZIL PROJECT |
| title_full | THE OUTCOME OF PERIPHERAL T-CELL LYMPHOMA PATIENTS FAILING FIRST-LINE THERAPY, FROM PROSPECTIVE COHORT OF T-CELL BRAZIL PROJECT |
| title_fullStr | THE OUTCOME OF PERIPHERAL T-CELL LYMPHOMA PATIENTS FAILING FIRST-LINE THERAPY, FROM PROSPECTIVE COHORT OF T-CELL BRAZIL PROJECT |
| title_full_unstemmed | THE OUTCOME OF PERIPHERAL T-CELL LYMPHOMA PATIENTS FAILING FIRST-LINE THERAPY, FROM PROSPECTIVE COHORT OF T-CELL BRAZIL PROJECT |
| title_short | THE OUTCOME OF PERIPHERAL T-CELL LYMPHOMA PATIENTS FAILING FIRST-LINE THERAPY, FROM PROSPECTIVE COHORT OF T-CELL BRAZIL PROJECT |
| title_sort | outcome of peripheral t cell lymphoma patients failing first line therapy from prospective cohort of t cell brazil project |
| url | http://www.sciencedirect.com/science/article/pii/S2531137923001992 |
| work_keys_str_mv | AT carminodesouza theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT elianamiranda theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT jamilatavares theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT renatalrbaptista theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT karinccecyn theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT julianapereira theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT marcelobellesso theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT samuelsmedina theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT davimarborducchi theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT fredericolnogueira theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT danielafcfarias theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT thaisfischer theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT ronyschaffel theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT massimofederico theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT carlosschiattone theoutcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT carminodesouza outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT elianamiranda outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT jamilatavares outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT renatalrbaptista outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT karinccecyn outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT julianapereira outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT marcelobellesso outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT samuelsmedina outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT davimarborducchi outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT fredericolnogueira outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT danielafcfarias outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT thaisfischer outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT ronyschaffel outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT massimofederico outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject AT carlosschiattone outcomeofperipheraltcelllymphomapatientsfailingfirstlinetherapyfromprospectivecohortoftcellbrazilproject |